• Return to Headlines

Relatively Low Projected Earnings Growth Detected in Shares of Repligen Corp in the Biotechnology Industry (RGEN, BMRN, AMGN, BIIB, MYGN)

By Amy Schwartz

Below are the three companies in the Biotechnology industry with the lowest projected earnings growth. The growth of earnings per share (current fiscal year estimated vs. last year actual) is important to gauge future profitability and relative value. Higher EPS growth generally justifies higher earnings multiples.

Repligen Corp ranks lowest with a projected earnings growth of 2.3%. Following is Biomarin Pharmac with a projected earnings growth of 3.3%. Amgen Inc ranks third lowest with a projected earnings growth of 9.0%.

Biogen Inc follows with a projected earnings growth of 9.3%, and Myriad Genetics rounds out the bottom five with a projected earnings growth of 13.9%.

SmarTrend recommended that subscribers consider buying shares of Repligen Corp on April 26th, 2019 as our technology indicated a new Uptrend was in progress when shares hit $63.79. Since that recommendation, shares of Repligen Corp have risen 16.3%. We continue to monitor Repligen Corp for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: lowest projected earnings growth repligen corp biomarin pharmac amgen inc biogen inc myriad genetics